Outcomes of transarterial embolization for large symptomatic focal nodular hyperplasia in 17 pediatric patients

Dig Liver Dis. 2023 Jul;55(7):899-906. doi: 10.1016/j.dld.2022.12.025. Epub 2023 Jan 19.

Abstract

Background: To evaluate the safety and the long-term outcomes of transarterial embolization (TAE) with lipiodol-bleomycin emulsion (LBE) plus N-Butyl cyanoacrylate (NBCA) in the treatment of children with large symptomatic focal nodular hyperplasia (FNH).

Methods: This is a retrospective case serial study. Children (aged <18 years) with FNH were treated. Indications for TAE were patients who were presenting with FNH related abdominal pain and the maximum diameter of FNH is more than 7 cm, and who were not candidates for surgical treatment. Technical success, adverse events, symptoms relief rate, and changes in the lesion size after TAE were evaluated.

Results: Between January 2003 and February 2018, 17 pediatric patients were included. Technical success was achieved in all patients. Mean follow-up was 67.5 months. All patients had complete resolution of abdominal symptom. The mean largest diameter of the lesions decreased from 10.5 cm to 1.9 cm (P < 0.01). The mean volume reduction rate was 96.9%. The complete resolution of the FNH was observed in 16 patients. No further therapy was needed for all patients.

Conclusions: TAE with LBE plus NBCA appears to be a safe and effective treatment in pediatric patients with large symptomatic FNH. It could be considered as the first-line treatment for symptomatic large FNH.

Keywords: Angiography; Embolization; Focal nodular hyperplasia; Liver neoplasm; Transarterial embolization.

MeSH terms

  • Bleomycin
  • Child
  • Embolization, Therapeutic* / adverse effects
  • Enbucrilate*
  • Ethiodized Oil
  • Focal Nodular Hyperplasia* / pathology
  • Focal Nodular Hyperplasia* / therapy
  • Humans
  • Retrospective Studies

Substances

  • Bleomycin
  • Ethiodized Oil
  • Enbucrilate